A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements

作者：Massimiliano Bonifacio, Luigi Scaffidi, Maria Cristina Miggiano, Davide Facchinelli, Luca Tosoni, Sara Pezone, Davide Griguolo, Giulia Ciotti, Marco Danini, Andrea Bernardelli, Rita Bresciani, Monica Cavraro, Lara Crosera, Elena De March, Michele Dell’Eva, Laura Dorotea, Luca Frison, Lara Furlani, Ilaria Gianesello, Ester Lovato, Elena Marchetti, Gianluca Morelli, Rikard Mullai, Umberto Pizzano, Simone Zoletto, Renato Fanin, Mauro Krampera, Livio Trentin, Elisabetta Calistri, Giuseppe Carli, Gianni Binotto, Mario Tiribelli · 发表于：Blood Cancer Journal · 年份：2024 · DOI：10.1038/s41408-024-01025-7 · 被引用次数：8 · 研究领域：Chronic Myeloid Leukemia Treatments、Chronic Lymphocytic Leukemia Research、Acute Myeloid Leukemia Research

The goal of achieving sustained treatment-free remission (TFR) after discontinuation of tyrosine kinase inhibitors (TKI) is of increasing importance in the management of chronic myeloid leukemia (CML) [ 1 ]. Different variables at diagnosis and, more importantly, upon response to treatment have been associated with distinct probabilities of a successful TFR. In an effort to expand access to TFR from the clinical trial setting to the wider clinical practice, “optimal” requirements which definitely prompt for treatment discontinuation have been proposed [ 2 , 3 ]. However, there is a lack of information about the outcome of patients who discontinue TKI treatment when one or more of these optimal requirements are missing.